[Significance of isoniazid for the therapy of experimental infection with total INH- and SM- resistant human tuberculosis bacteria in the mice].
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D007275:Injections, Intravenous; D007538:Isoniazid / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D007612:Kanamycin / Q000627:therapeutic use; D051379:Mice; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D010670:Phenylthiourea / Q000031:analogs & derivatives / Q000627:therapeutic use; D013307:Streptomycin / Q000494:pharmacology* / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*; D014756:Viomycin / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D007612:Kanamycin; D010670:Phenylthiourea; D004977:Ethambutol; D005000:Ethionamide; D007538:Isoniazid; D013307:Streptomycin; D014756:Viomycin
Die Bedeutung von Isoniazid für die Therapie der Experimentellen Infektion der Maus mit Total INH- und SM- Resistenten Humanen Tuberkulosebakterien Stamm Schacht)